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 Microvascular obstruction (MVO), which represents failed myocardial reperfusion, 78 
occurs in about half of patients treated with standard primary percutaneous coronary 79 
intervention (PCI), and predicts a worse prognosis.1 Distal embolization and microvascular 80 
thrombosis contribute to MVO. In the T-TIME trial (NCT02257294),2 we hypothesized that 81 
low-dose intracoronary fibrinolysis with alteplase, in patients with adequate anticoagulation 82 
undergoing primary PCI, would reduce MVO extent as assessed by contrast enhanced 83 
cardiovascular magnetic resonance imaging. We found that MVO did not differ with 84 
alteplase vs. placebo.2 Here, we report the efficacy and safety of intracoronary alteplase at 1-85 
year.  86 
From August 2016 to December 2017, patients with acute ST-segment elevation 87 
myocardial infarction from 11 U.K. hospitals were prospectively enrolled. The trial design 88 
and main results have been described previously.2 T-TIME was an investigator-initiated, 89 
double-blind, parallel-group, randomized, placebo-controlled clinical trial. Patients were 90 
eligible if they presented with persistent ST-elevation or recent left bundle branch block, ≤6 91 
hours from symptom onset, and either an occluded culprit artery, or impaired flow (TIMI 92 
[Thrombolysis in Myocardial Infarction] flow grade 2) with TIMI thrombus grade ≥2. The 93 
study was approved by the West of Scotland Research Ethics Committee (reference 13-WS-94 
0119). Informed consent was obtained. 95 
Patients were randomized to placebo, alteplase 10mg, or alteplase 20mg, on a 1:1:1 96 
basis. The intervention was administered before stent implantation by manual infusion of the 97 
20ml volume of study into the culprit artery proximal to the lesion. Serious adverse events 98 
with potential relevance to the pre-defined clinical outcomes, were adjudicated by a blinded 99 
clinical event committee. Analysis of efficacy outcomes was according to treatment as 100 
randomized. Analysis of major bleeds was based on treatment received. Logistic regression 101 




(adjusted for infarct location) was used to assess for treatment effects. Statistical analyses 102 
were performed with Rv3.2.4, according to a pre-specified statistical analysis plan. 103 
Four hundred and forty patients (mean age 61±10 years, 85% male) were randomized 104 
to placebo (n=151), alteplase 10mg (n=144) and alteplase 20mg (n=145) (Figure). At 1-year, 105 
there was no difference in MACE (major adverse cardiac events) with alteplase 20mg (n=15 106 
[10.3%]) vs. placebo (n=16 [10.6%]) (OR [odds ratio]: 0.96 [95% CI (confidence interval): 107 
0.45, 2.04]), or with alteplase 10mg (n=22 [15.3%]) vs. placebo (OR: 1.52 [95% CI: 0.76, 108 
3.05]). There was no difference in spontaneous MACE (MACE excluding MI associated with 109 
revascularization) at 1-year with alteplase 20mg (n=14 [ 9.7%]) vs. placebo (n=16 [10.6%]) 110 
(OR: 0.89 [95% CI: 0.42, 1.91]), or with alteplase 10mg (n=18 [12.5%]) vs. placebo (OR: 111 
1.19 [95% CI: 0.58, 2.46]). MI associated with revascularization occurred in 2, 4 and 1 112 
patients at 1-year, randomized to placebo, alteplase 10mg and alteplase 20mg respectively 113 
(log rank p=0.351). 114 
MACCE (major adverse cardiovascular and cardiac events), defined as cardiovascular 115 
death, non-fatal MI, or unplanned hospitalization for stroke, or transient ischemic attack, did 116 
not differ between treatment groups at 1-year (alteplase 20mg [n=10 (6.9%)] vs. placebo 117 
[n=7 (4.6%)]: OR: 1.54 [95% CI: 0.57, 4.16]; or alteplase 10mg [n=9 (6.3%)] vs. placebo: 118 
OR: 1.38 [95% CI: 0.50, 3.83]). Similarly, there was no difference in the composite of all-119 
cause mortality and heart failure hospitalization, with alteplase 20mg (n=13 [9.0%]) vs. 120 
placebo (n=14 [9.3%]) (OR: 0.95 [95% CI: 0.43, 2.12]), or with alteplase 10mg (n=19 121 
[13.2%]) vs. placebo (OR: 1.48 [95% CI: 0.71, 3.12]). There was no difference in heart 122 
failure hospitalizations at 1-year with alteplase 20mg (n=10 [6.9%]) vs. placebo (n=13 123 
[8.6%]) (OR: 0.76 [95% CI: 0.32, 1.84]), or with alteplase 10mg (n=15 [10.4%]) vs. placebo 124 
(OR: 1.22 [95% CI: 0.55, 2.72]). There was no difference in all-cause death at 1-year, with 125 
placebo (n=1 [0.7%]), alteplase 10mg (n=6 [4.2%]), or alteplase 20mg (n=3 [2.1%]) (log-126 




rank p=0.127). BARC (Bleeding Academic Research Consortium) type 3-5 bleeds occurred 127 
in 1, 2 and 2 patients, with placebo, alteplase 10mg and alteplase 20mg (log-rank p=0.792). 128 
In summary, clinical outcomes at 1-year were not improved by adjunctive, low-dose, 129 
intracoronary fibrinolysis. Bleeds were uncommon (1.1%) and consistent with what would be 130 
expected in a contemporary primary-PCI population. These results should be interpreted as 131 
exploratory because the T-TIME trial was designed but not powered to examine 1-year 132 
clinical outcomes.  133 
Potential for harm with facilitated PCI, using full- or half-dose fibrinolytic therapy 134 
given intravenously pre-PCI, was shown in the ASSENT-43 and FINESSE4 trials. 135 
Intravenous fibrinolytic therapy pre-PCI improved initial culprit artery patency, but increased 136 
residual thrombus, ischemic complications and major bleeds, compared to standard primary 137 
PCI.5 These results could be explained by inadequate anticoagulation compounded by any 138 
paradoxical prothrombotic effects of lytic therapy in P2Y12 inhibitor naive-patients.  139 
 Current trials of adjunctive intracoronary fibrinolysis during primary PCI include 140 
RESTORE-MI [NCT03998319], STRIVE [NCT0335839], and OPTIMAL [NCT02894138]. 141 
Further research should build on the new knowledge arising from T-TIME, to elucidate 142 
which patient groups might benefit.   143 
In conclusion, low-dose intracoronary alteplase administered early during primary 144 
PCI did not improve clinical outcomes. Further research is warranted to identify new 145 
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Figure. Screening, randomization, treatment, and follow up at one year. 176 
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